Open AccessClinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Author(s) -
Mary Ann Anderson,
Constantine S. Tam,
Thomas E. Lew,
Surender Juneja,
Manu Juneja,
David Westerman,
Meaghan Wall,
Stephen Lade,
Alexandra Gorelik,
David C.S. Huang,
John F. Seymour,
Andrew W. Roberts
Publication year - 2017
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood-2017-01-763003
Subject(s) - venetoclax , ibrutinib , medicine , chronic lymphocytic leukemia , oncology , cancer research , leukemia
Key Points Complex karyotype and fludarabine refractoriness are key risk factors for progression of CLL on venetoclax. Bruton tyrosine kinase inhibitors are active in patients with CLL after prior therapy with venetoclax.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom